CFO Jack Anders Buys Shares of Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc.'s Chief Financial Officer, Jack Anders, made a notable move by purchasing 20,000 shares of the company on June 24, 2026. This insider transaction did not specify the purchase price or total value, but it highlights a potential vote of confidence from within the company.

Insider Buying and Selling at Revolution Medicines, Inc.

Jack Anders, the CFO of Revolution Medicines, was active in the market on June 24, 2026. He acquired 20,000 shares in a direct purchase, and separately, he sold 20,000 shares at an average price of $168.33 as part of a planned transaction. This dual action suggests a strategic approach to managing his holdings in the company. Additionally, other insiders like Lorence Kim, Flavia Borellini, and Sushil Patel were involved in buying activities earlier in June, each purchasing shares without specifying the price.

Revolution Medicines, Inc. Stock Down 12.4%

Shares of Revolution Medicines, Inc. (NasdaqGS:RVMD) traded near $182.08 on Saturday. The company, valued at approximately $38.71 billion, operates with a forward P/E ratio of -31.93, indicating it is not currently profitable. With a beta of 1.41, the stock has shown some volatility. Over the past year, it has ranged from a low of $34.00 to a high of $184.39. The stock's 50-day moving average is $151.23, and its 200-day moving average is $98.50, suggesting recent upward momentum.

Analysts Set New Price Targets

Analysts continue to show strong interest in Revolution Medicines, with Evercore ISI Group maintaining a 'buy' rating and setting a price target of $220.00 on June 10, 2026. RBC Capital also reiterated its 'buy' rating with a target of $182.00 on June 2, 2026. Overall, the analyst consensus is a 'strong buy', with an average target price of $188.57 from 21 analysts, reflecting a positive outlook for the company.

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for RAS-addicted cancers. Based in Redwood City, California, the company is led by CEO Dr. Mark A. Goldsmith. It employs 883 people and is known for its innovative RAS(ON) inhibitors, which target specific cancer mutations. Revolution Medicines' pipeline includes several promising candidates in various stages of clinical development.

Bottom Line

Jack Anders' recent share acquisition at Revolution Medicines underscores insider confidence in the company's future. While the stock remains volatile, analysts maintain a strong buy consensus, suggesting optimism about its potential. As always, investors should note that insider transactions are disclosed after they occur and may not reflect current intentions.